Oncourology. The latest technologies in today’s realities: the results of the PROfound study — the efficacy and safety profile of olaparib in mCRPC
Summary. Prostate cancer treatment requires the introduction of new therapeutic approaches to improve treatment outcomes. Currently, targeted drugs, the choice of which is based on the results of genetic testing, are at the fore in the treatment of metastatic castrate-resistant prostate cancer. Recently, the arsenal of Ukrainian oncologists was replenished with another targeted drug — the PARP inhibitor olaparib. As part of the seminar «Oncourology. The latest technologies in today’s realities» reviewed recommendations for the use of genetic testing methods, as well as the evidence base for the use of the PARP inhibitor olaparib in metastatic castrate-resistant prostate cancer.
Leave a comment